{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:56:44Z","timestamp":1768093004307,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","award":["16973"],"award-info":[{"award-number":["16973"]}],"id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005187","name":"National and Kapodistrian University of Athens","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005681","name":"Genesis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005681","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.nmd.2021.09.008","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T17:05:03Z","timestamp":1632935103000},"page":"1251-1258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the country"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-8377","authenticated-orcid":false,"given":"Georgios","family":"Koutsis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoi","family":"Kontogeorgiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrisoula","family":"Kartanou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Kokotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michail","family":"Rentzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianthi","family":"Breza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kleopas A.","family":"Kleopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0622-7594","authenticated-orcid":false,"given":"Kyproula","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Oikonomou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aris","family":"Anastasakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Angelidakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Sarmas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odysseas","family":"Kargiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minas","family":"Tzagournissakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-5772","authenticated-orcid":false,"given":"Ioannis","family":"Zaganas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Foukarakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-9257","authenticated-orcid":false,"given":"Vasileios","family":"Sachpekidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Papathoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Panas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3569-8990","authenticated-orcid":false,"given":"Leonidas","family":"Stefanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Karadima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.nmd.2021.09.008_bib0001","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nmd.2021.09.008_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.nmd.2021.09.008_bib0003","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/13506120802676948","article-title":"Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus","volume":"16","author":"Dardiotis","year":"2009","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"10.1016\/j.nmd.2021.09.008_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/13506129.2012.685665","article-title":"Regional difference and similarity of familial amyloidosis with polyneuropathy in France","volume":"19","author":"Adams","year":"2012","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.nmd.2021.09.008_bib0005","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jnnp-2015-310907","article-title":"A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK","volume":"87","author":"Carr","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.nmd.2021.09.008_bib0006","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.nmd.2016.04.013","article-title":"Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey","volume":"26","author":"Durmu\u015f-Tek\u00e7e","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"Suppl 1","key":"10.1016\/j.nmd.2021.09.008_bib0007","doi-asserted-by":"crossref","first-page":"O6","DOI":"10.1186\/1750-1172-10-S1-O6","volume":"10","author":"Tzagournissakis","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 15","key":"10.1016\/j.nmd.2021.09.008_bib0008","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1212\/WNL.94.15_supplement.3974","article-title":"High prevalence of transthyretin-related amyloidosis in crete, Greece is due to three TTR pathogenic variants with markedly differing phenotypic presentations","volume":"94","author":"Tzagournissaki","year":"2020","journal-title":"Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2021.09.008_bib0009","first-page":"195","article-title":"A case of familial amyloid polyneuropathy type I of Greek origin","volume":"15","author":"Rafailidis","year":"2002","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.nmd.2021.09.008_bib0010","first-page":"367","article-title":"[A case of type I familial amyloidpolyneuropathy]","volume":"78","author":"Papanicolaou","year":"2000","journal-title":"Iatriki"},{"issue":"24","key":"10.1016\/j.nmd.2021.09.008_bib0011","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2021.09.008_bib0012","unstructured":"Gen Secr Natl Stat Serv Greece. http:\/\/www.statistics.gr\/portal\/page\/ESYE\/PAGE-themes. [accessed November 11, 2020 ]"},{"issue":"9","key":"10.1016\/j.nmd.2021.09.008_bib0013","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum Mutat"},{"issue":"6","key":"10.1016\/j.nmd.2021.09.008_bib0014","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","article-title":"Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France","volume":"78","author":"Mariani","year":"2015","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2021.09.008_bib0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00415-017-8640-7","article-title":"Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan","volume":"265","author":"Yamashita","year":"2018","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.nmd.2021.09.008_bib0016","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1212\/WNL.58.7.1001","article-title":"Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity","volume":"58","author":"Ikeda","year":"2002","journal-title":"Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2021.09.008_bib0017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/13506121003619369","article-title":"Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy","volume":"17","author":"Tojo","year":"2010","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.nmd.2021.09.008_bib0018","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506129.2019.1634539","article-title":"Founder effect of the Glu89Gln TTR mutation in the Bulgarian population","volume":"26","author":"Kirov","year":"2019","journal-title":"Amyloid"},{"issue":"12","key":"10.1016\/j.nmd.2021.09.008_bib0019","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/jmg.29.12.888","article-title":"A new mutant transthyretin (Arg 10) associated with familial amyloid polyneuropathy","volume":"29","author":"Uemichi","year":"1992","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.nmd.2021.09.008_bib0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/jmg.32.4.279","article-title":"A new transthyretin variant (Ser 24) associated with familial amyloid polyneuropathy","volume":"32","author":"Uemichi","year":"1995","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.nmd.2021.09.008_bib0021","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/13506129.2012.724035","article-title":"Familial amyloid polyneuropathy associated with the novel transthyretin variant Arg34Gly","volume":"19","author":"Levy","year":"2012","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.nmd.2021.09.008_bib0022","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/(SICI)1096-8628(19980501)77:2<135::AID-AJMG5>3.0.CO;2-R","article-title":"Novel transthyretin missense mutation (Thr34) in an Italian family with hereditary amyloidosis","volume":"77","author":"Patrosso","year":"1998","journal-title":"Am J Med Genet"},{"issue":"3","key":"10.1016\/j.nmd.2021.09.008_bib0023","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506120308998998","article-title":"Tabulation of human transthyretin (TTR) variants, 2003","volume":"10","author":"Connors","year":"2003","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.nmd.2021.09.008_bib0024","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/13506120701616383","article-title":"Transthyretin valine-94-alanine, a novel variant associated with late-onset systemic amyloidosis with cardiac involvement","volume":"14","author":"Kristen","year":"2007","journal-title":"Amyloid"},{"issue":"10","key":"10.1016\/j.nmd.2021.09.008_bib0025","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/ejhf.1285","article-title":"Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure","volume":"20","author":"Gagliardi","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.nmd.2021.09.008_bib0026","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/13506120009146824","article-title":"A novel variant of transthyretin (Glu89Lys) associated with familial amyloidotic polyneuropathy","volume":"7","author":"Nakamura","year":"2000","journal-title":"Amyloid"},{"issue":"8","key":"10.1016\/j.nmd.2021.09.008_bib0027","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"17","key":"10.1016\/j.nmd.2021.09.008_bib0028","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.nmd.2021.09.008_bib0029","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.nmd.2021.09.008_bib0030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.transproceed.2019.01.071","article-title":"Liver transplantation for familial amyloid polyneuropathy (val30met): long-term follow-up prospective study in a nontransplant center","volume":"51","author":"Kavousanaki","year":"2019","journal-title":"Transplant Proc"},{"issue":"8","key":"10.1016\/j.nmd.2021.09.008_bib0031","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis fo transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621006544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621006544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:11:54Z","timestamp":1760775114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621006544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0960896621006544"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.09.008","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the country","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}